- Originally developed to treat type 2 diabetes, some GLP-1 agonists have been approved to treat obesity. They mimic the actions of the endogenous incretin hormone GLP-1, which is released in the small intestine and can inhibit glucagon release and increase insulin secretion.
- GLP-1 receptor agonists and GLP-1 and glucose-dependent insulinotropic peptide agonists have several mechanisms of action, including reduction of gastric emptying, inhibition of glucagon secretion, beneficial changes in the intestinal microbiome, and direct effects on hypothalamic nuclei to enhance satiety (which promotes weight loss).
- Glucagon-like peptide-1 (GLP-1) ... options for these endocrine diseases. The function of GLP-1 agonists is to lower serum glucose levels and thereby manage metabolism in affected patients....
- Triple agonists go even further.148 ... obesity.150,152,153 Activation of the GLP-1R can enhance insulin secretion, reduce glucagon secretion, delay gastric emptying,154 and suppress appetite.155,156 GIPR activation also promotes insulin ...
- The development of dual and triple agonists was based on technical advances enabling the synthesis of peptides combining amino acid sequences from various peptide hormones, with the resulting hybrid being able to interact with two or more relevant receptors. The rationale to address glucagon receptor activity was anchored in studies of obese rodents, which showed that long-acting glucagon agonists decrease bodyweight and improve glucose control via mechanisms that include suppression of energy intake, elevation of energy expenditure, stimulation of lipolysis, and lipid use.6,7 GLP-1glucagon
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for the management of type 2 diabetes, have gained prominence in managing obesity, offering clinically meaningful weight loss of 1520% in many clinical trials.1 The ...
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are widely used in the treatment of type 2 diabetes and potential applications may include the treatment of obesity as well as the adjunctive treatment of type 1 diabetes mellitus in combination with insulin.
